Amneal Pharmaceuticals, INC Form 4 insider transactions

Nikita Shah, Executive Vice President of Amneal Pharmaceuticals, reports multiple transactions involving Class A Common Stock and Restricted Stock Units.

Executive Vice President Andrew Boyer reports the vesting of restricted stock units and subsequent stock transactions in Amneal Pharmaceuticals.

Executive Vice President and CFO of Amneal Pharmaceuticals, Tasos Konidaris, reports the vesting of restricted stock units and subsequent tax withholding.

Nikita Shah, Executive Vice President of Amneal Pharmaceuticals, reports the vesting of restricted stock units and subsequent tax withholding.

Director Gautam Patel sold 80,000 shares of Amneal Pharmaceuticals (AMRX) at an average price of $8.14 on February 3, 2025, according to a Form 4 filing.

Gautam Patel, a director at Amneal Pharmaceuticals, sold 62,590 shares of Class A Common Stock at an average price of $8.01 per share under a pre-arranged 10b5-1 trading plan.

Director Gautam Patel sold 17,410 shares of Amneal Pharmaceuticals Class A Common Stock on January 2, 2025, at an average price of $8.01 per share.

Amneal Pharmaceuticals director John Kiely exercised stock options and sold a portion of the acquired shares on November 22, 2024.

Director Deborah M. Autor sold a total of 39,990 shares of Amneal Pharmaceuticals Class A Common Stock in two separate transactions on November 21 and 22, 2024.

Amneal Pharmaceuticals' SVP, Chief Legal Officer, Jason B. Daly, sold 13,665 shares of Class A Common Stock at $8.40 per share on November 21, 2024.

Amneal Pharmaceuticals' SVP, Chief Legal Officer, Jason B. Daly, sold 43,657 shares of Class A Common Stock at a weighted average price of $8.61.

Executive Vice President Andrew Boyer of Amneal Pharmaceuticals sold a portion of his Class A Common Stock holdings on August 14 and 15, 2024.

Nikita Shah, Executive Vice President of Amneal Pharmaceuticals, sold 100,000 shares of Class A Common Stock on August 14, 2024, at a weighted average price of $7.75 per share.

Director Deborah M. Autor sold shares of Amneal Pharmaceuticals to cover tax withholding obligations related to the vesting of restricted stock units.

Director Emily Peterson Alva exercised stock options for 76,453 shares of Amneal Pharmaceuticals Class A Common Stock on May 10, 2024.

Director Deborah M. Autor reports vesting of restricted stock units into Class A Common Stock of Amneal Pharmaceuticals.

Director Paul M. Meister reported a transaction involving Amneal Pharmaceuticals' Class A Common Stock, acquiring 107,034 shares through the vesting of restricted stock units.

Director John Kiely disposed of 76,453 shares of Amneal Pharmaceuticals Class A Common Stock on May 10, 2024, following the vesting of restricted stock units.

Director Jeffrey P. George acquired 76,453 shares of Amneal Pharmaceuticals Class A Common Stock through the vesting of restricted stock units on May 10, 2024.

Director Kevin Buchi disposed of 76,453 shares of Amneal Pharmaceuticals Class A Common Stock on May 10, 2024, through the vesting of restricted stock units.

Director Ted C. Nark of Amneal Pharmaceuticals reports the vesting of 76,453 restricted stock units, resulting in ownership of 300,771 Class A Common Stock shares.

Director Shlomo Yanai of Amneal Pharmaceuticals reports the vesting of 76,453 restricted stock units, convertible to Class A Common Stock, on May 10, 2024.

Director Gautam Patel reports vesting of restricted stock units and acquisition of Class A Common Stock in Amneal Pharmaceuticals.

Director Yanai Shlomo of Amneal Pharmaceuticals acquired 40,258 restricted stock units on May 2, 2024.

Director Gautam Patel acquired 40,258 restricted stock units in Amneal Pharmaceuticals, Inc. on May 2, 2024.

Director Ted C. Nark acquired 40,258 restricted stock units of Amneal Pharmaceuticals, Inc. on May 2, 2024.

Director John Kiely acquired 40,258 restricted stock units of Amneal Pharmaceuticals, Inc. on May 2, 2024.

Director Jeffrey P. George acquired 40,258 restricted stock units in Amneal Pharmaceuticals, Inc.

J Kevin Buchi, a director at Amneal Pharmaceuticals, acquired 40,258 restricted stock units on May 2, 2024, according to a Form 4 filing with the SEC.

Deborah M. Autor, a director at Amneal Pharmaceuticals, was granted 40,258 restricted stock units on May 2, 2024.